The last pre-pandemic European Renal Association Registry report: age at start of kidney replacement therapy in Europe

Carriazo, Sol; Ortíz, Alberto

doi:10.1093/ckj/sfab274

Cited by 5 publications

(1 citation statement)

References 12 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The impact of practice variation on outcomes should be studied. The UK also has a less proactive approach in providing kidney replacement therapy than other Western European countries [ 22 ]. Interestingly, life expectancy at birth is similar in Germany and the UK, but higher in the Netherlands and Italy, and lower in Poland [ 23 ].…”

Section: Cardiovascular Diseasesmentioning

confidence: 99%

Ageing meets kidney disease

Ortíz

Mattace‐Raso

Soler

et al. 2022

Clinical Kidney Journal

Self Cite

View full text Add to dashboard Cite

Chronic kidney disease (CKD) is defined as abnormalities of kidney structure or function, present for ˃3 months, with implications for health. The most used diagnostic criteria are a urinary albumin: creatinine ratio ≥30 mg/g or an estimated glomerular filtration rate (eGFR) <60 mL/min/1.73 m2. Either of these diagnostic thresholds is associated with adverse health outcomes. GFR decreases with age and the prevalence of CKD is highest in older adults; moreover, the presence of CKD is associated with an increased risk of all-cause and cardiovascular death related to accelerated ageing in all age ranges, and the absolute increase in risk is highest for those aged ˃75 years. Indeed, premature death is a more common outcome than CKD progression to kidney failure requiring kidney replacement therapy. The progressive ageing of the world population contributes to the projection that CKD will become the second most common cause of death before the end of the century in countries with long life expectancy. The current collection of selected studies on kidney disease and ageing published in Age&Ageing, NDT and CKJ provides an overview of key topics, including cognitive decline, sarcopaenia, wasting and cardiovascular and non-cardiovascular morbidity and mortality, the management of kidney failure and gender differences in CKD progression.

show abstract

Section: Cardiovascular Diseasesmentioning

confidence: 99%

Ageing meets kidney disease

Ortíz

Mattace‐Raso

Soler

et al. 2022

Clinical Kidney Journal

Self Cite

View full text Add to dashboard Cite

show abstract

The Broader Effects of Delayed Progression to End-Stage Kidney Disease: Delaying the Inevitable or a Meaningful Change?

Correa-Rotter,

Wheeler,

McEwan

2024

Adv Ther

View full text Add to dashboard Cite

A global rise in the prevalence of patients with chronic kidney disease (CKD) with end-stage kidney disease (ESKD) has led to a considerable and increasing burden to health systems, patients, and society. Sodium–glucose cotransporter 2 (SGLT2) inhibitors are proven to reduce incidence of cardio-renal outcomes, including onset of ESKD. Recent post hoc analyses of SGLT2 inhibitor trials extrapolate substantial delays in the average time to ESKD over a patient’s lifetime. In this article, we explore the possible real-world effects of such a delay by considering the available evidence reporting outcomes following onset of ESKD. From the patient perspective, a delay in reaching ESKD could substantially improve health-related quality of life and result in additional life years without the need for kidney replacement therapies, a target relevant to all CKD subpopulations. Furthermore, should a patient initiate dialysis at an older age as a result of CKD progression, the time spent in receipt of dialysis, and therefore associated healthcare costs, may also be reduced. A delay in progression may also lead to changes in the management of ESKD, such as increased election of conservative care in preference to dialysis, particularly in elderly populations. For younger patients with CKD, those who reach ESKD while employed face considerable work impairment and productivity loss, as may families and care partners of working age. Therefore, a delay to the onset of ESKD will reduce the proportion of their working lives affected by productivity losses or unemployment due to medical reasons. In conclusion, optimised treatment of CKD may lead to a shift in treatment options, but proper and timely implementation is essential for the realisation of improved outcomes.

show abstract

Ageing meets kidney disease

et al. 2022

View full text Add to dashboard Cite

Chronic kidney disease (CKD) is defined as abnormalities of kidney structure or function, present for longer than 3 months, with implications for health. The most used diagnostic criteria are a urinary albumin:creatinine ratio ≧30 mg/g or an estimated glomerular filtration rate (eGFR) <60 mL/min/1.73 m2. Either of these diagnostic thresholds are associated to adverse health outcomes. GFR decreases with age and the prevalence of CKD is highest in older adults; moreover, the presence of CKD is associated with an increased risk of all-cause and cardiovascular death related to accelerated ageing in all age ranges, and the absolute increase in risk is highest for those aged over 75 years. Indeed, premature death is a more common outcome than CKD progression to kidney failure requiring kidney replacement therapy. The progressive ageing of the world population contributes to the projection that CKD will become the second commonest cause of death before the end of the century in countries with long life expectancy. The current collection of selected studies on kidney disease and ageing published in Age&Ageing, NDT, and CKJ provides an overview of key topics, including cognitive decline, sarcopenia, wasting and cardiovascular and non-cardiovascular morbidity and mortality, the management of kidney failure and gender differences in CKD progression.

show abstract

The last pre-pandemic European Renal Association Registry report: age at start of kidney replacement therapy in Europe

Cited by 5 publications

References 12 publications

Ageing meets kidney disease

Ageing meets kidney disease

The Broader Effects of Delayed Progression to End-Stage Kidney Disease: Delaying the Inevitable or a Meaningful Change?

Ageing meets kidney disease

Contact Info

Product

Resources

About